A Plus Biotechnology Co Ltd

A Plus Biotechnology Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 5.71, indicating that the company has more than five times the current assets to cover its current liabilities. However, the company's liquidity risk is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt. The debt-to-equity ratio of 0.12 suggests a conservative capital structure, with a relatively small amount of long-term debt compared to equity.

In terms of profitability, the company's return on equity (ROE) of 4.13% and return on assets (ROA) of 3.24% are below the typical thresholds for high-performing firms in the medical equipment and supplies industry. These metrics suggest that the company is generating modest returns relative to its equity and asset base. Gross profit of TWD 125,506,000 and operating income of TWD 41,430,000 indicate a healthy gross margin, but the net income of TWD 35,855,000 suggests that operating expenses are consuming a significant portion of the gross profit.

The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns implies that the business may be relatively undiversified in terms of product lines or geographic exposure. This could pose a risk if demand for its core products declines or if it faces regulatory or supply chain disruptions in its primary markets.

Looking ahead, the company's growth trajectory is not explicitly outlined in the available data. However, the current revenue of TWD 177,925,000 provides a baseline for assessing future performance. The absence of detailed outlook data means that the company's ability to sustain or grow its revenue in the coming fiscal years is uncertain.

The risk assessment highlights a low dilution potential, with no significant dilution sources identified in the available data. The company's capital structure remains stable, with no recent issuance or shelf registration activity reported. However, the negative net cash position after subtracting total debt is a concern and may require closer monitoring in the near term.

Recent events, such as filings or transcripts, are not detailed in the available data. Therefore, the company's strategic direction and operational performance in the most recent periods cannot be assessed based on disclosed events.

Revenue grew at an 11.4% CAGR over four years, demonstrating consistent top-line expansion for the biotechnology company.

Net income surged with a 50.6% CAGR over four years, highlighting significant profitability growth relative to revenue.

Debt-to-equity ratio of 0.12 is below the cohort median of 0.2, suggesting a conservative and stable capital structure.

Long-term debt increased to TWD 212.2 million in FY-4, reversing a previous trend of debt reduction.

The company faces medium liquidity risk, which could constrain operational flexibility or short-term financial stability.

Medium credit risk flags suggest potential challenges in maintaining favorable borrowing terms or credit ratings.

Return on equity of 4.1% remains modest despite high margins, indicating potential inefficiencies in capital utilization.